Serrated tubulovillous adenoma of the large intestine

Histopathology

Volumn 68, Issue 4, 2016, Pages 578-587

  Bettington, Mark ^a,b,c   Walker, Neal ^b,c   Rosty, Christophe ^b,c,d   Brown, Ian ^c,e   Clouston, Andrew ^b,c,e   Mckeone, Diane ^a   Pearson, Sally Ann ^a   Klein, Kerenaftali ^a   Leggett, Barbara ^a,b,f   Whitehall, Vicki ^a,b,e  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c Envoi Specialist Pathologists   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e Pathology Queensland ^*  (Australia)

^f ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Adenoma; Colonic polyps; Serrated; Traditional serrated adenoma; Tubulovillous adenoma

Indexed keywords

B RAF KINASE; BETA CATENIN; CYTOKERATIN 20; CYTOKERATIN 7; K RAS PROTEIN; KI 67 ANTIGEN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROTEIN MLH1; PROTEIN P16; PROTEIN P53; TUMOR MARKER;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTESTINE POLYP; LARGE INTESTINE SERRATED TUBULOVILLOUS ADENOMA; LARGE INTESTINE TUMOR; MALE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN METHYLATION; AGED; COLON TUMOR; DNA MUTATIONAL ANALYSIS; GENETICS; MIDDLE AGED; PATHOLOGY; VILLOUS ADENOMA;

ADENOMA, VILLOUS; AGED; BIOMARKERS, TUMOR; COLONIC NEOPLASMS; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED;

EID: 84957935923     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12788     Document Type: Article

References (33)

1. Bosman FT, World Health Organization, International Agency for Research on Cancer. WHO classification of tumours of the digestive system, 4th edn. Lyon: International Agency for Research on Cancer, 2010.
2. Sinicrope FA, Shi Q, Smyrk TC et al. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes. Gastroenterology 2015; 148; 88-99.
3. Phipps AI, Limburg PJ, Baron JA et al. Association between molecular subtypes of colorectal cancer and patient survival. Gastroenterology 2015; 148; 77-87.
4. Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 2007; 50; 113-130.
5. Bettington M, Walker N, Clouston A, Brown I, Leggett B, Whitehall V. The serrated pathway to colorectal carcinoma: current concepts and challenges. Histopathology 2013; 62; 367-386.
6. Leggett B, Whitehall V. Role of the serrated pathway in colorectal cancer pathogenesis. Gastroenterology 2010; 138; 2088-2100.
7. Jass JR, Baker K, Zlobec I et al. Advanced colorectal polyps with the molecular and morphological features of serrated polyps and adenomas: concept of a 'fusion' pathway to colorectal cancer. Histopathology 2006; 49; 121-131.
8. Bettington M, Walker N, Rosty C et al. Critical appraisal of the diagnosis of the sessile serrated adenoma. Am. J. Surg. Pathol. 2014; 38; 158-166.
9. Bettington ML, Walker NI, Rosty C et al. A clinicopathological and molecular analysis of 200 traditional serrated adenomas. Mod. Pathol. 2015; 28; 414-427.
10. Hafezi-Bakhtiari S, Wang LM, Colling R, Serra S, Chetty R. Histological overlap between colorectal villous/tubulovillous and traditional serrated adenomas. Histopathology 2015; 66; 308-313.
11. Chetty R, Hafezi-Bakhtiari S, Serra S, Colling R, Wang LM. Traditional serrated adenomas (TSAs) admixed with other serrated (so-called precursor) polyps and conventional adenomas: a frequent occurrence. J. Clin. Pathol. 2015; 68; 270-273.
12. Fu B, Yachida S, Morgan R, Zhong Y, Montgomery EA, Iacobuzio-Donahue CA. Clinicopathologic and genetic characterization of traditional serrated adenomas of the colon. Am. J. Clin. Pathol. 2012; 138; 356-366.
13. Tsai JH, Liau JY, Lin YL et al. Traditional serrated adenoma has two pathways of neoplastic progression that are distinct from the sessile serrated pathway of colorectal carcinogenesis. Mod. Pathol. 2014; 27; 1375-1385.
14. Makinen MJ. Colorectal serrated adenocarcinoma. Histopathology 2007; 50; 131-150.
15. Young J, Barker MA, Simms LA et al. Evidence for BRAF mutation and variable levels of microsatellite instability in a syndrome of familial colorectal cancer. Clin. Gastroenterol. Hepatol. 2005; 3; 254-263.
16. Whitehall V, Tran K, Umapathy A et al. A multicenter blinded study to evaluate KRAS mutation testing methodologies in the clinical setting. J. Mol. Diagn. 2009; 11; 543-552.
17. Weisenberger DJ, Siegmund KD, Campan M et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat. Genet. 2006; 38; 787-793.
18. Whitehall VL, Rickman C, Bond CE et al. Oncogenic PIK3CA mutations in colorectal cancers and polyps. Int. J. Cancer 2012; 131; 813-820.
19. Esteller M, Toyota M, Sanchez-Cespedes M et al. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. Cancer Res. 2000; 60; 2368-2371.
20. Odze RD, Goldblum JR, eds. Surgical pathology of the GI tract, liver, biliary tract and pancreas, 2nd ed. Philadelphia: Saunders Elsevier, 2009.
21. Pai RK, Mackinnon AC, Joseph L, Noffsinger A, Hart J. Identification of histologically distinct conventional adenomas that arise predominately in patients with sessile serrated adenomas. Am. J. Surg. Pathol. 2010; 34; 355-363.
22. Kakar S, Deng G, Cun L, Sahai V, Kim YS. CpG island methylation is frequently present in tubulovillous and villous adenomas and correlates with size, site, and villous component. Hum. Pathol. 2008; 39; 30-36.
23. Ishii T, Notohara K, Umapathy A et al. Tubular adenomas with minor villous changes show molecular features characteristic of tubulovillous adenomas. Am. J. Surg. Pathol. 2011; 35; 212-220.
24. Maltzman T, Knoll K, Martinez ME et al. Ki-ras proto-oncogene mutations in sporadic colorectal adenomas: relationship to histologic and clinical characteristics. Gastroenterology 2001; 121; 302-309.
25. Yadamsuren EA, Nagy S, Pajor L, Lacza A, Bogner B. Characteristics of advanced- and non advanced sporadic polypoid colorectal adenomas: correlation to KRAS mutations. Pathol. Oncol. Res. 2012; 18; 1077-1084.
26. Makinen MJ, George SM, Jernvall P, Makela J, Vihko P, Karttunen TJ. Colorectal carcinoma associated with serrated adenoma - prevalence, histological features, and prognosis. J. Pathol. 2001; 193; 286-294.
27. Stefanius K, Ylitalo L, Tuomisto A et al. Frequent mutations of KRAS in addition to BRAF in colorectal serrated adenocarcinoma. Histopathology 2011; 58; 679-692.
28. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002; 418; 934.
29. Baas IO, Mulder JW, Offerhaus GJ, Vogelstein B, Hamilton SR. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J. Pathol. 1994; 172; 5-12.
30. Longacre TA, Fenoglio-Preiser CM. Mixed hyperplastic adenomatous polyps/serrated adenomas. A distinct form of colorectal neoplasia. Am. J. Surg. Pathol. 1990; 14; 524-537.
31. Torlakovic E, Skovlund E, Snover DC, Torlakovic G, Nesland JM. Morphologic reappraisal of serrated colorectal polyps. Am. J. Surg. Pathol. 2003; 27; 65-81.
32. Torlakovic EE, Gomez JD, Driman DK et al. Sessile serrated adenoma (SSA) vs. traditional serrated adenoma (TSA). Am. J. Surg. Pathol. 2008; 32; 21-29.
33. Lieberman DA, Rex DK, Winawer SJ, Giardiello FM, Johnson DA, Levin TR. Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology 2012; 143; 844-857.